Search Results

Reaction Biology (“Reaction” or the “Company”), an industry-leading provider of drug discovery and development services, today announced that it will feature its recently launched HotSpot™ ATP-Max KinomeScreen at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 7-10, 2024, in San Diego, California.

ARS Pharma’s neffy on Friday became the first FDA-approved nasal spray to address severe allergic reactions, including those that might lead to life-threatening anaphylaxis.

Cytokinetics, Incorporated announced that the Company will host the muscle biology-focused Contemporary Landscapes in Muscle Biology Research Symposium , May 17th, 2024 at the Mission Bay Conference Center in San Francisco.

ARS Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion on the application for marketing authorization for EURneffy® and recommended related market authorization in the European Union for the emergency treatment of allergic reactions.

Approximately 10% of people diagnosed with cancer experience hypersensitivity reactions to certain therapies—which range from a mild skin rash to anaphylaxis —even when they were pretreated with antihistamines and steroids.

Protect Pharmaceutical Corp.'s (OTC: PRTT) (“Company”) President, Ali Yildiz, provides its shareholders with the following informational update: “July 1, 2024 Dear Shareholders: The Company’s PCAOB audit for the fiscal year of 2023 is near completion.

Tonix Pharmaceuticals Holding Corp. today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the Phase 2 investigator-initiated OASIS trial to evaluate TNX-102 SL1 in reducing the severity of acute stress reaction (ASR) and the frequency of acute stress disorder (ASD) and posttraumatic stress disorder (PTSD).

Apotex Corp. announced the launch of Cetrorelix Acetate for Injection 0.25mg, a generic version of Cetrotide® in the United States.

MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company” or “MustGrow”), is pleased to announce the results of its 2024 annual meeting of shareholders (the “Meeting”) held on June 27, 2024.

Reaction Biology (“Reaction” or the “Company”) today announced that eleven abstracts highlighting data from the Company’s expanding suite of research offerings will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14-19, 2023, in Orlando, Florida.